Skip to main content
. 2021 Jul 1;8(17):2004381. doi: 10.1002/advs.202004381

Figure 5.

Figure 5

Anti‐GBM effect of ZGO@TiO2@ALP‐NEs. a) Experimental schedule for the therapy and long‐term immune‐surveillance against GBM with ultrasound triggered ZGO@TiO2@ALP‐NEs. b) Histological study and c) survival analysis of saline, Taxol (3 mg kg−1), NEs (5 × 106 cells/mouse), ZGO@TiO2@ALP (3 mg kg−1 PTX), ZGO@TiO2@ALP‐NEs (5 × 106 cells/mouse), and ZGO@TiO2@ALP‐NEs + US (5 × 106 cells/mouse, US: 5 min, 1.5 MHz, 1.5 W cm−2) treated tumor‐bearing mice. GBM regions were indicated by the dotted lines. d) Survival plot for GBM rechallenged long‐term survivors from (c) ZGO@TiO2@ALP‐NEs + US treatment group (n = 4) and control mice (n = 10). ***P < 0.001, **P < 0.01.